Small molecule biotechnology company Iambic Therapeutics (IAM.US) sets IPO price at $15-17 per share, plans to raise $150 millions

智通财经2026/10/09 07:06

Show original

According to Jinse Finance, it has been reported that Iambic Therapeutics (IAM.US), a biotechnology company developing small-molecule anti-cancer therapies based on its self-developed artificial intelligence (AI) platform and currently in Phase I clinical trials, announced its IPO terms on Thursday. The San Diego, California-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. Some investors have already expressed their intention to purchase $60 million worth of shares in this offering, accounting for 40% of the deal. At the midpoint of the proposed price range, Iambic Therapeutics would have a fully diluted market value of $809 million.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Dana Gas reports suspected drone attack on Iraq Kurdistan Khor Mor gas field, production halted

智通财经•2026/11/09 05:16

Earnings Preview | Applied Materials (AMAT.US) Q4 Results are Certain, the Real Focus is on the Missing 2027 Quantitative Guidance

Applied Materials' high growth in revenue and profit this quarter is already certain. What truly determines the stock price is the guidance for fiscal year 2027, changes in gross margin, and the marginal changes in China-related risks.

智通财经•2026/11/09 04:37

Earnings Preview | Applied Materials (AMAT.US) Q4 Results Hold No Surprises; The Real Focus Is the Yet-to-be-Given 2027 Quantitative Guidance

智通财经•2026/11/09 04:36

Nomura’s dominance is being challenged! Mizuho (MFG.US) is reshaping Japan’s underwriting landscape with global IPOs

智通财经•2026/11/09 03:51